We performed a nested case-control study (ratio of 1:4) on the emergence of tigecycline-resistant multidrug-resistant Klebsiella pneumoniae (TR-MDRKP) isolates among patients who initially presented with a tigecycline-susceptible MDRKP isolate. Out of 260 patients, 24 (9%) had a subsequent clinical culture positive for a TR-MDRKP isolate within the 90-day follow-up period. On logistic regression analyses, receipt of tigecycline (adjusted odds ratio [OR], 5.06; 95% confidence interval [CI], 1.80 to 14.23; P ‫؍‬ 0.002) was the only independent predictor of subsequent isolation of a TR strain.
T
igecycline, a minocycline derivative, remains one of the few therapeutic options for the treatment of infections caused by multidrug-resistant Klebsiella pneumoniae (MDRKP) isolatesincluding Klebsiella pneumoniae carbapenemase (KPC) producers-and other Gram-negative organisms (1, 2) . Of concern, tigecycline nonsusceptibility (i.e., tigecycline resistance [TR]) among Klebsiella pneumoniae isolates has been reported from different continents and ranged between 0% and 11.5% in a recent large study (3) (4) (5) (6) . Furthermore, several recent case studies identified patients who were treated with tigecycline for an initially tigecycline-susceptible MDRKP (TS-MDRKP) infection but from whom a TR-MDRKP strain was subsequently isolated (7) (8) (9) (10) . However, the potential of in vivo emergence of TR among MDRKP isolates has so far not been systematically investigated to our knowledge. We intended to study the rates of and risk factors for the in vivo emergence of TR among Klebsiella pneumoniae isolates in a large population of patients who initially presented with a TS-MDRKP.
We performed a nested case-control study on the subsequent emergence of TR among all patients from whom a TS-MDRKP strain was previously isolated at a tertiary care center between January 2008 and July 2011. MDRKP was defined as the presence of either an extended-spectrum ␤-lactamase (ESBL)-or KPCproducing Klebsiella pneumoniae isolate, determined as per Clinical and Laboratory Standards Institute (CLSI) guidelines on ESBL testing, carbapenem resistance patterns, and Hodge test results, respectively (11, 12) . Food and Drug Administration (FDA) breakpoints were applied to interpret the results of tigecycline susceptibility testing using the disc diffusion method and Etest (susceptible if the zone diameter is Ն19 mm and the isolate MIC is Յ2 g/ml, respectively).
A case was defined as a patient from whom a TR-MDRKP was isolated between Ͼ48 h and Ͻ90 days after the day a TS-MDRKP strain was isolated (zero time). A control was defined as a patient from whom a TS-MDRKP strain was isolated during the study period but with no subsequent TR-MDRKP strains. Controls were matched to cases based on the isolate's resistance mechanism (ESBL versus KPC) but otherwise randomly selected in a 1:4 ratio. Cases were compared to controls with regard to a variety of demographic and clinical characteristics. We also recorded (i) all antibiotic exposures within 90 days before zero time and (ii) all antibiotic exposures between zero time and the day on which a culture positive for a TR-MDRKP isolate was obtained (cases) or all antibiotic exposures within 90 days after zero time (controls). Patients with cultures positive for a TR-MDRKP organism any time before or on the day of isolation of a TS-MDRKP strain and patients with incomplete medical records or inadequate follow-up were excluded.
Bivariate analyses using the Pearson's chi-square test, Fisher's exact test, or the Mann-Whitney U test were performed to compare categorical and continuous variables as indicated. Logistic regression models were used to determine independent predictors of subsequent isolation of a TR-MDRKP isolate (P Ͻ 0.05); variables with a P value of Ͻ0.2 on bivariate analyses and plausible interaction terms were entered into the model. TS-MDRKP strains were isolated from 276 patients during the observation period; 16 patients were excluded according to the criteria listed above. Among a total of 260 patients who were included into our cohort, 155 (60%) had a KPC isolate, and 105 (40%) had an ESBL isolate. Among these 260 patients, 24 (9%; 95% confidence interval [CI], 6.3 to 13.4%) had a subsequent clinical specimen culture positive for a TR-MDRKP isolate within our defined follow-up period; 18 (75%) of the 24 isolates were KPCs. These 24 case patients were compared to 96 matched individuals without subsequent TR-MDRKP (n ϭ 120) in a nested case-control study. The median age of these patients was 73 years (range, 23 to 97 years), 59 (49%) were male, and the median Charlson comorbidity score was 3 (13) . MDRKP was most commonly isolated from urine specimens at zero time (61%). Among the 96 control patients, 39 (41%) had at least one additional culture positive for TS-MDRKP within the follow-up period, whereas 57 patients had no subsequent MDRKP strain isolated.
Cases and controls were similar with regard to a variety of demographic and clinical characteristics, days of hospitalization, isolate source, clinical infection versus colonization with a TS-MDRKP isolate at zero time, presence of a medical device, and exposure to multiple antibiotic classes before and after zero time (Tables 1 and 2 ). In contrast, 18 (75%) of 24 cases versus only 32 (33%) of 96 controls were treated with tigecycline for a median duration of 9 days (range, 2 to 33 days) after zero time (P Ͻ 0.001 on bivariate analysis) ( Table 2 ). On backward logistic regression analyses, receipt of tigecycline after zero time (adjusted odds ratio [OR], 5.06; 95% CI, 1.80 to 14.23; P ϭ 0.002) was the only independent predictor of subsequent isolation of a TR strain.
MDRKP infections are associated with high attributable mortality rates of up to 50% (14) ; for patients with infections caused by KPC isolates, tigecycline remains one of the few therapeutic options besides aminoglycosides and colistin. Our study found a high rate (9%) of in vivo TR emergence among patients who initially presented with a TS-MDRKP strain in the previous 90 days; exposure to tigecycline was the only independent predictor of subsequent resistance. These results build on and expand our knowledge from several recent case reports that describe the occurrence of TR-MDRKP among patients recently treated with tigecycline monotherapy or combination therapy (7, 8, 9, 10, 15) . In our study, MDRKP isolation from the urinary tract or other body sites where low tigecycline concentrations are achieved was not associated with emergence of TR. This finding is interesting as achievable tigecycline concentrations in the urine are low (only 10% to 22% is excreted unaltered), and tigecycline treatment failure rates of up to 57% were observed in patients with urinary tract infections caused by KPC producers (16) .
Molecular typing of initial and subsequent isolates was not performed in our study. Thus, the selection of a genetically distinct TR strain that was previously present below detection levels by tigecycline exposure cannot be excluded in our study; however, prior studies using molecular typing methodologies suggest the in vivo emergence of TR in previously drug-susceptible strains upon drug exposure (7) . TR is mediated by the overexpression of the efflux pump AcrAB-TolC (17) . Our retrospective study design did not include an algorithm that required standardized follow-up culturing of patients from whom TS-MDRKP was previously iso- a ZT, zero time; T/C, ticarcillin-clavulanate; P/T, piperacillin-tazobactam; "4th generation," extremely broad spectrum of activity.
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